Advanced

Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.

Koivula, Robert LU ; Heggie, Alison; Barnett, Anna; Cederberg, Henna; Hansen, Tue H; Koopman, Anitra D; Ridderstråle, Martin LU ; Rutters, Femke; Vestergaard, Henrik and Gupta, Ramneek, et al. (2014) In Diabetologia 57(6). p.1132-1142
Abstract
The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetologia
volume
57
issue
6
pages
1132 - 1142
publisher
Springer
external identifiers
  • pmid:24695864
  • wos:000335922800006
  • scopus:84901229328
ISSN
1432-0428
DOI
10.1007/s00125-014-3216-x
language
English
LU publication?
yes
id
a23d1af8-b6e9-4f25-b9d9-388f6a45ccb7 (old id 4431161)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24695864?dopt=Abstract
date added to LUP
2014-05-06 21:37:06
date last changed
2019-08-14 01:16:58
@article{a23d1af8-b6e9-4f25-b9d9-388f6a45ccb7,
  abstract     = {The DIRECT (Diabetes Research on Patient Stratification) Study is part of a European Union Framework 7 Innovative Medicines Initiative project, a joint undertaking between four industry and 21 academic partners throughout Europe. The Consortium aims to discover and validate biomarkers that: (1) predict the rate of glycaemic deterioration before and after type 2 diabetes onset; (2) predict the response to diabetes therapies; and (3) help stratify type 2 diabetes into clearly definable disease subclasses that can be treated more effectively than without stratification. This paper describes two new prospective cohort studies conducted as part of DIRECT.},
  author       = {Koivula, Robert and Heggie, Alison and Barnett, Anna and Cederberg, Henna and Hansen, Tue H and Koopman, Anitra D and Ridderstråle, Martin and Rutters, Femke and Vestergaard, Henrik and Gupta, Ramneek and Herrgård, Sanna and Heymans, Martijn W and Perry, Mandy H and Rauh, Simone and Siloaho, Maritta and Teare, Harriet J A and Thorand, Barbara and Bell, Jimmy and Brunak, Søren and Frost, Gary and Jablonka, Bernd and Mari, Andrea and McDonald, Tim J and Dekker, Jacqueline M and Hansen, Torben and Hattersley, Andrew and Laakso, Markku and Pedersen, Oluf and Koivisto, Veikko and Ruetten, Hartmut and Walker, Mark and Pearson, Ewan and Franks, Paul},
  issn         = {1432-0428},
  language     = {eng},
  number       = {6},
  pages        = {1132--1142},
  publisher    = {Springer},
  series       = {Diabetologia},
  title        = {Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium.},
  url          = {http://dx.doi.org/10.1007/s00125-014-3216-x},
  volume       = {57},
  year         = {2014},
}